RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Prothena Corporation Stock

Prothena Corporation P/E 2024

Prothena Corporation P/E

-9.36

Ticker

PRTA

ISIN

IE00B91XRN20

WKN

A1KAVV

As of Oct 6, 2024, Prothena Corporation's P/E ratio was -9.36, a -61.05% change from the -24.03 P/E ratio recorded in the previous year.

The Prothena Corporation P/E history

Prothena Corporation Aktienanalyse

What does Prothena Corporation do?

Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Prothena Corporation's P/E Ratio

The Price to Earnings (P/E) Ratio of Prothena Corporation is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Prothena Corporation's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Prothena Corporation is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Prothena Corporation’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Prothena Corporation stock

What is the price-to-earnings ratio of Prothena Corporation?

The price-earnings ratio of Prothena Corporation is currently -9.36.

How has the price-earnings ratio of Prothena Corporation changed compared to last year?

The price-to-earnings ratio of Prothena Corporation has increased by -61.05% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Prothena Corporation high compared to other companies?

Yes, the price-to-earnings ratio of Prothena Corporation is high compared to other companies.

How does an increase in the price-earnings ratio of Prothena Corporation affect the company?

An increase in the price-earnings ratio of Prothena Corporation would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Prothena Corporation affect the company?

A decrease in the price-earnings ratio of Prothena Corporation would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Prothena Corporation?

Some factors that influence the price-earnings ratio of Prothena Corporation are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Prothena Corporation pay?

Over the past 12 months, Prothena Corporation paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Prothena Corporation is expected to pay a dividend of 0 USD.

What is the dividend yield of Prothena Corporation?

The current dividend yield of Prothena Corporation is .

When does Prothena Corporation pay dividends?

Prothena Corporation pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Prothena Corporation?

Prothena Corporation paid dividends every year for the past 0 years.

What is the dividend of Prothena Corporation?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Prothena Corporation located?

Prothena Corporation is assigned to the 'Health' sector.

Wann musste ich die Aktien von Prothena Corporation kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Prothena Corporation from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Prothena Corporation pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Prothena Corporation in the year 2023?

In the year 2023, Prothena Corporation distributed 0 USD as dividends.

In which currency does Prothena Corporation pay out the dividend?

The dividends of Prothena Corporation are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Prothena Corporation

Our stock analysis for Prothena Corporation Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Prothena Corporation Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.